Clinical Trials Browser

Enrolling by invitation × INDUSTRY × Interventional × Clear all

NCT06435312 2026-04-13

ziMyG+

Phase 3 Enrolling by invitation

Myasthenia Gravis

NCT06540144 2026-04-13

An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis

Phase 3 Enrolling by invitation

Myasthenia Gravis

NCT06788509 2026-04-13

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

Phase 1 Enrolling by invitation

GenitourinaryLymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Prostatic Neoplasms, Castration-Resistant

NCT06940648 2026-04-13

VIABLE

Phase NA Enrolling by invitation

Urinary Bladder Neoplasms

NCT07296263 2026-04-13

Contrast PMR

Phase NA Enrolling by invitation

Infections

NCT06506955 2026-04-03

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

Phase 2/3 Enrolling by invitation

Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

NCT05303532 2026-03-24

ROSY-D

Phase 3 Enrolling by invitation

Neoplasms

NCT06763965 2026-03-23

Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.

Phase 1/2 Enrolling by invitation

Adenoviridae Infections, Glioma

NCT07126990 2026-03-23

Clinical Study of a Novel Oncolytic Virus Ad-TD-nsIL12 in the Treatment of Primary High-grade Glioma

Phase 1/2 Enrolling by invitation

Glioma

NCT07218003 2026-03-23

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

Phase 1 Enrolling by invitation

BreastGastrointestinalGenitourinaryGynecologicThoracic

Esophageal Squamous Cell Carcinoma, Adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT05441475 2026-02-25

A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients

Phase 2 Enrolling by invitation

Gastrointestinal

Carcinoma, Hepatocellular

NCT07116668 2026-02-18

SAFE-3CV

Phase NA Enrolling by invitation

Gastrointestinal

Colorectal Neoplasms

NCT05374590 2026-02-02

ADAPT Jr +

Phase 2/3 Enrolling by invitation

Myasthenia Gravis

NCT07376629 2026-01-29

A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC

Phase 2 Enrolling by invitation

TNBC

NCT05645536 2026-01-12

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

Phase 3 Enrolling by invitation

Breast Neoplasms, Neoplasms

NCT06848088 2026-01-12

A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment

Phase 2 Enrolling by invitation

Melanoma

NCT07316361 2026-01-07

GYNORYLAQ™

Phase EARLY_PHASE1 Enrolling by invitation

Endometrial Neoplasms

NCT06281964 2025-12-16

KANNON-2

Phase 3 Enrolling by invitation

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07285434 2025-12-16

Microlyvaq™

Phase EARLY_PHASE1 Enrolling by invitation

Carcinoma, Non-Small-Cell Lung

NCT06215846 2025-11-26

A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors

Phase 1 Enrolling by invitation

Adenoviridae Infections

NCT06603987 2025-11-19

Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA

Phase 1/2 Enrolling by invitation

BreastGastrointestinalOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neurofibrosarcoma

NCT04093570 2025-10-31

A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

Phase 2 Enrolling by invitation

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT06544798 2025-10-16

Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia

Phase 2 Enrolling by invitation

Lymphoma, Follicular

NCT07210047 2025-10-07

Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients

Phase 1/2 Enrolling by invitation

Multiple Myeloma

NCT05423977 2025-09-30

Study of ZV0203 in Patients With HER2-Positive Advanced Solid Tumors

Phase 1 Enrolling by invitation

Other solid neoplasm

HER2-positive Advanced Solid Tumor

NCT06674538 2025-09-22

Clinical Trial to Treat Stage IV Cancer Patients

Phase 1 Enrolling by invitation

Neoplasms, Sarcoma

NCT06945640 2025-09-16

HTK_002

Phase NA Enrolling by invitation

Kidney Neoplasms

NCT06936527 2025-09-03

XS-03-II201

Phase 1/2 Enrolling by invitation

Gastrointestinal

Colorectal Neoplasms

NCT03628612 2025-08-07

Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells

Phase 2 Enrolling by invitation

LymphoidPlasma cell

Multiple Myeloma, Lymphoma, T-Cell

NCT07061769 2025-07-11

Helping Cancer Patients Manage Neuropathy Symptoms From Chemotherapy With a Low-Intensity, Low-Risk Cranial PEMF Device

Phase NA Enrolling by invitation

Chemotherapy Induced Peripheral Neuropathy

NCT07053904 2025-07-08

Phase I Open-Label Study of P1101 Followed by P1801 in Advanced Solid Tumors

Phase 1 Enrolling by invitation

Other solid neoplasm

Advanced Solid Tumors

NCT07046832 2025-07-02

Clinical Evaluation of an Augmented Reality Intraprocedural Needle Guidance Platform for Soft Tissue Biopsy

Phase NA Enrolling by invitation

GastrointestinalGenitourinary

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Neoplasms

NCT06992687 2025-05-28

A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors

Phase 1/2 Enrolling by invitation

Other solid neoplasm

Solid Tumors

NCT04915495 2025-03-21

The Use of the LuViva Advanced Cervical Scan to Identify Women at High-Risk for Cervical Neoplasia

Phase NA Enrolling by invitation

Uterine Cervical Dysplasia, Uterine Cervical Neoplasms

NCT04145375 2025-03-19

Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol

Phase 1/2 Enrolling by invitation

Prostatic Neoplasms

NCT06780358 2025-01-17

RAISE02

Phase NA Enrolling by invitation

Urinary Bladder Neoplasms

NCT03311451 2025-01-13

C2 CryoBalloon™ 180 Ablation System Dose De-escalation Study.

Phase NA Enrolling by invitation

Gastrointestinal

Barrett Esophagus

NCT06759857 2025-01-06

FHND9041

Phase 3 Enrolling by invitation

Carcinoma, Non-Small-Cell Lung

NCT06755515 2025-01-01

A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

Phase 2/3 Enrolling by invitation

Uterine Cervical Neoplasms

NCT06747832 2024-12-24

iNK-SCLC

Phase EARLY_PHASE1 Enrolling by invitation

Small Cell Lung Carcinoma

NCT06169579 2024-11-15

An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers

Phase 1 Enrolling by invitation

Other solid neoplasm

Advanced Solid Tumor

NCT06616727 2024-09-27

The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM

Phase 1 Enrolling by invitation

Glioblastoma

NCT06587152 2024-09-19

Clinical Trial to Evaluate the Efficacy and Safety of a Thoracic and Abdominal Endoscopic Surgical System

Phase NA Enrolling by invitation

Gastrointestinal

Esophageal Neoplasms, Colorectal Neoplasms

NCT06245031 2024-05-07

Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)

Phase NA Enrolling by invitation

Alzheimer Disease, Dementia, Lymphoma, Follicular, Cognitive Dysfunction

NCT05865925 2024-04-25

Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors

Phase 1/2 Enrolling by invitation

Other solid neoplasm

Advanced Solid Tumors

NCT06205082 2024-03-01

A Phase I Clinical Trial to Evaluate LIT-00814 Tablets in Patients With Advanced Solid Tumor

Phase 1 Enrolling by invitation

Other solid neoplasm

Advanced Solid Tumor